Scarica l'app Stockscreener
9.59
0.95%
0.09
Precedente Chiudi:
$9.50
Aprire:
$9.39
Volume 24 ore:
313.41K
Relative Volume:
0.38
Capitalizzazione di mercato:
$440.15M
Reddito:
$10.32M
Utile/perdita netta:
$-89.93M
Rapporto P/E:
-3.9852
EPS:
-2.4064
Flusso di cassa netto:
$-88.63M
1 W Prestazione:
-0.62%
1M Prestazione:
-14.37%
6M Prestazione:
-54.49%
1 anno Prestazione:
+103.61%
Intervallo 1D:
$9.39
$9.76
Intervallo di 1 settimana:
$9.1501
$10.05
Portata 52W:
$4.58
$25.95
Bioage Labs Inc Stock (BIOA) Company Profile
Nome
Bioage Labs Inc
Settore
Telefono
510-806-1445
Indirizzo
5885 HOLLIS STREET, EMERYVILLE
Compare BIOA vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
9.59 | 444.74M | 10.32M | -89.93M | -88.63M | -2.4064 |
TAK
Takeda Pharmaceutical Co Adr
|
18.45 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.36 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.60 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.81 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
487.61 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-05-27 | Iniziato | Roth Capital | Buy |
| 2026-05-13 | Iniziato | BTIG Research | Buy |
| 2026-03-27 | Iniziato | Needham | Buy |
| 2026-02-25 | Iniziato | Oppenheimer | Outperform |
| 2026-02-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2026-01-27 | Iniziato | Piper Sandler | Overweight |
| 2025-12-05 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2025-10-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-02-28 | Iniziato | William Blair | Mkt Perform |
| 2024-12-10 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | Downgrade | Citigroup | Buy → Neutral |
| 2024-12-09 | Downgrade | Jefferies | Buy → Hold |
| 2024-10-21 | Iniziato | Citigroup | Buy |
| 2024-10-21 | Iniziato | Jefferies | Buy |
| 2024-10-21 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Bioage Labs Inc Borsa (BIOA) Ultime notizie
354,395 Shares in BioAge Labs, Inc. $BIOA Bought by Walleye Capital LLC - MarketBeat
BioAge Labs, Inc.: Shareholders Board Members Managers and Company Profile | US09077V1008 - marketscreener.com
Cormorant Asset Management (BIOA) discloses 5.38% BioAge Labs ownership stake - Stock Titan
214,546 Shares in BioAge Labs, Inc. $BIOA Purchased by Dimensional Fund Advisors LP - MarketBeat
BioAge Labs, Inc. (NASDAQ:BIOA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Renaissance Technologies LLC Buys 120,188 Shares of BioAge Labs, Inc. $BIOA - MarketBeat
BIOA Q2 2026 Earnings: Narrower-than-Expected Loss Offers Modest ReliefEarnings Stability Report - vinanet.vn
We're Not Very Worried About BioAge Labs' (NASDAQ:BIOA) Cash Burn Rate - Moomoo
BioAge Labs (BIOA) Retreats 2.3% Toward Key Support as Momentum FadesCash Secured Put - dars.gov.et
Morgan Stanley Maintains BioAge Labs(BIOA.US) With Hold Rating, Cuts Target Price to $20 - Moomoo
Roth MKM Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Analysts’ Opinions Are Mixed on These NA Stocks: BioAge Labs, Inc. (BIOA) and Fiserv (FISV) - The Globe and Mail
BIOA News & Events - Intellectia AI
BIOAGE Labs Inc (BIOA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BIOAGE Labs Inc (BIOA) Stock News Today - TradingKey
A Quick Look at Today's Ratings for BioAge Labs(BIOA.US), With a Forecast Between $21 to $73 - Moomoo
BioAge Labs, Inc. Stock 12‑Month Price Target Cut to $35.62, Implies 224% Upside - TradingView
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
BioAge Labs (NASDAQ:BIOA) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS - MarketBeat
BioAge Labs, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
BIOA: BGE-102 clinical trials advanced, net loss increased, and cash reserves remain strong - TradingView
BioAge Labs reports Q2 2026 net loss $26.1M, cash and securities $381.3M; BGE-102 Phase 2 dosing underway - TradingView
BioAge Labs, Inc. Q2 2026: Revenue $2.45M, EPS $(0.58) — 10-Q Summary - TradingView
BioAge Labs (NASDAQ: BIOA) builds $381.3M cash buffer as BGE-102 advances - Stock Titan
BioAge Labs | 10-Q: Q2 2026 Earnings Report - Moomoo
BioAge Labs Reports Q2 2026 Results, Doses First Patient in QUELL-CV and Advances BGE-102 Clinical Development - Quiver Quantitative
BioAge Labs, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
BioAge's BGE-102 Enters Obesity Trial; Eye Study Planned - Stock Titan
Price to earnings forward of BioAge Labs, Inc. – SWB:Y7G - TradingView
BIOA Q2'26 Earnings: revenue estimate is 1.50M USD - TradingView
Piper Sandler Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $73 - Moomoo
BioAge Labs posts partial recovery after deep selloff, rises 19% (BIOA:NASDAQ) - Seeking Alpha
Weekly Recap: ZEUS miss lifts BGE-102 and Analysts cut BIOA PTs, keep Buy - TradingView
Janus Henderson Group PLC Acquires 1,685,063 Shares of BioAge Labs, Inc. $BIOA - MarketBeat
BioAge Labs (BIOA) Surges 19% as Shares Approach Key Resistance at $11.32Regression Channel - vinanet.vn
Why is BioAge Labs stock plunging today? By Investing.com - Investing.com Canada
Why is BioAge Labs stock plunging 60% today? By Investing.com - Investing.com Canada
BioAge Labs (BIOA) Surges 12% as Momentum Builds Past Key Support LevelOversold Bounce Ideas - vinanet.vn
BIOA|BIOAGE Labs Inc|Price:20.850|Chg%:-0.920 - TradingKey
BIOAGE Labs Inc (BIOA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BIOAGE Labs Inc (BIOA) Valuation: PE, PB & Fair Value Analysis - TradingKey
BioAge Labs, Inc. $BIOA Shares Sold by Orbimed Advisors LLC - MarketBeat
Octagon Capital Advisors LP Has $30.57 Million Stock Position in BioAge Labs, Inc. $BIOA - MarketBeat
The Gross Law Firm Notifies Shareholders of BioAge Labs, Inc.(BI - GuruFocus
BIOAGE Labs Inc (BIOA) Income Statement - TradingKey
TradingKey - TradingKey
BIOAGE Labs Inc (BIOA) Balance Sheet - TradingKey
BIOAGE Labs Inc (BIOA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BIOAGE Labs Inc (BIOA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BIOA|BIOAGE Labs Inc|Price:10.540|Chg%:+0.060 - TradingKey
Bioage Labs Inc Azioni (BIOA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Bioage Labs Inc Azioni (BIOA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Barton Shane | Principal Accounting Officer |
Jun 30 '26 |
Option Exercise |
6.53 |
20,216 |
132,017 |
20,216 |
| Barton Shane | Principal Accounting Officer |
Jun 29 '26 |
Sale |
25.21 |
42,350 |
1,067,576 |
0 |
| Barton Shane | Principal Accounting Officer |
Jun 30 '26 |
Sale |
25.19 |
20,216 |
509,176 |
0 |
1.66%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):